Inozyme Pharma, Inc. (INZY)
NASDAQ: INZY · Real-Time Price · USD
1.010
+0.010 (1.03%)
Mar 14, 2025, 10:01 AM EDT - Market open
Inozyme Pharma Stock Forecast
INZY's stock price has decreased by -82.52% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Inozyme Pharma stock have an average target of 16.9, with a low estimate of 11 and a high estimate of 30. The average target predicts an increase of 1,573.27% from the current stock price of 1.01.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Inozyme Pharma stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 2 | 2 | 2 | 3 | 3 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 8 | 8 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Buy Maintains $24 → $12 | Buy | Maintains | $24 → $12 | +1,088.12% | Mar 12, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $30 → $23 | Buy | Maintains | $30 → $23 | +2,177.23% | Mar 11, 2025 |
| Needham | Needham | Strong Buy Maintains $23 → $15 | Strong Buy | Maintains | $23 → $15 | +1,385.15% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +1,484.16% | Mar 11, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $43 → $30 | Buy | Maintains | $43 → $30 | +2,870.30% | Jan 13, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
10.53M
EPS This Year
-1.57
from -1.62
EPS Next Year
-1.68
from -1.57
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 39.1M | 238.2M | ||
| Avg | n/a | 10.5M | 81.7M | ||
| Low | n/a | n/a | 2.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 2,162.2% | ||
| Avg | - | - | 676.2% | ||
| Low | - | - | -72.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.06 | -0.96 | -0.72 | ||
| Avg | -1.57 | -1.68 | -1.00 | ||
| Low | -1.96 | -2.19 | -1.25 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.